May 2026 Newsletter: A Selective Reopening of the Biotech IPO Window
- Jun 1
- 4 min read
Dear colleagues, April 2026 saw four biotech initial public offerings (IPOs) price at the top of their marketed ranges, raising approximately $1.5 billion in aggregate gross proceeds. Early aftermarket trading has been constructive overall, though performance has already separated across the cohort. The deals signal a meaningful, but selective, thawing of the IPO window. Public investors are engaging, but the bar remains high: April’s issuers all brought clinical-stage assets, deep crossover support, and visible near-term catalysts. In this issue, we share our read on April’s biotech IPO activity, the drivers behind the current window, and where investor expectations remain unchanged.  Thank you to everyone who connected with Heather at AACR in San Diego. Headland team members will also be attending upcoming conferences, including ASCO in Chicago and BIO in San Diego. Please use this link to book a meeting time at ASCO and this link to schedule through BIO Partnering. |
April’s IPO class: What public investors rewarded. April’s four biotech IPOs shared a common profile: each priced at the top of its marketed range, raised scale capital, and gave investors a defined clinical path. Kailera Therapeutics (KLRA) raised $625 million for Phase 3 ribupatide development in obesity and type 2 diabetes; Avalyn Pharma (AVLN) raised an upsized $300 million offering to advance reformulated respiratory drugs in pulmonary fibrosis; Hemab Therapeutics (COAG) raised an upsized offering of approximately $300 million to advance bispecific antibodies for rare coagulation disorders; and Seaport Therapeutics (SPTX) raised an upsized offering of approximately $255 million to fund Phase 1 and Phase 2 neuropsychiatric programs. In early trading, performance began to separate across the cohort. Kailera, Avalyn, and Hemab traded materially above issue in their first days as public companies, while Seaport’s move was more modest. By the first week of May, that separation had sharpened, with Kailera, Avalyn, and Hemab still more than 35% above issue and Seaport trading below issue. Relative to XBI over the same period, that performance gap points to stock-specific demand for selected new issues, not simply broader biotech market movement.  The market-adjusted read reinforces the selectivity of demand. April’s strongest performers paired clinical-stage assets with strong sponsorship and visible catalysts. The next test is durability, with 30-, 60-, and 90-day trading performance likely to shape how quickly the next wave of issuers can access the market. Investor filters: How investors are weighing biotech risk. The current interest rate environment continues to favor biotech companies with visible clinical or strategic milestones. With the Federal Reserve holding interest rates at 3.50% to 3.75% on April 29 and futures implying limited easing through year-end, investors are still operating in a disciplined cost-of-capital environment. Public investors are placing more weight on companies with credible 12 to 24-month catalysts, while platform or discovery-led stories with longer timelines remain harder to underwrite. This filter is reinforced by renewed pharma demand for external innovation. As we covered in last month’s newsletter on Q1 2026 biopharma BD, large-cap pharma is deploying capital at scale. Merck reported approximately $9 billion in business development spending in Q1 2026, and Eli Lilly has announced six clinical-stage acquisitions so far this year. This creates de-risking for public investors, who now have two value-creating paths to underwrite clinical-stage companies with defined indications: standalone development success, and strategic takeout by pharma. Hemab and Seaport illustrate how earlier clinical-stage companies de-risk their programs to clear the bar. Both arrived at IPO with crossover-validated syndicates. Hemab’s $157 million Series C was led by Sofinnova Partners, and Seaport’s $225 million Series B was led by General Atlantic with participation from T. Rowe Price, Foresite Capital, and Goldman Sachs Alternatives. On the asset side, their de-risking diverged. Hemab leaned on three-layered proof points for sutacimig. The company pointed to completed Phase 2 data in Glanzmann thrombasthenia, FDA Breakthrough Therapy Designation in March 2026, and a registrational study planned for the second half of 2026. Seaport leaned on a single near-term catalyst. GlyphAllo, an oral neurosteroid prodrug, is approaching a Phase 2b topline readout that public investors are effectively buying as the company’s next inflection point. De-risking now happens on multiple layers, including crossover validation upstream, BD comparables at exit, and regulatory designations or named near-term catalysts at the asset level. For teams, the practical IPO question is whether the next value-creating event is clear enough to anchor a public investor’s underwriting. Let's talk. Whether you're preparing for an IPO or evaluating an opportunity on the buy side, Headland continues to be a trusted partner to clients looking to develop and pressure-test commercial, BD/M&A, pipeline, and Medical Affairs strategy when the stakes are high. Feel free to reach out to us at solutions@headlandstrategy.com to discuss how we can support your corporate development strategy. This month's newsletter was researched and drafted by Headland Associate Kaitlyn Ryu. |
What we are reading and listening to. A short list of external resources we are finding helpful:
|